FDA approves JJ Intranasal Ketamine for Depression
Posted: Jan 22, 2025
- FDA approved Johnson & Johnson's ketamine-derived nasal spray Spravato for treatment-resistant depression
- Esketamine is a molecular mirror-image of ketamine that can be given as a nasal spray
- Spravato is aimed at people who have tried two antidepressant drugs with no improvement
- Janssen, a division of Johnson & Johnson, will sell Spravato at a wholesale cost of $590-$885 per treatment
- Patients receiving Spravato must go to a certified facility for administration under supervision
- Clinical trials show that about one in five to ten patients treated with esketamine will benefit
Stay ahead of the market with AI stock alerts & AI summaries of the latest earnings, stock ideas for free with Fluid Bot. Sign up now!